It was a pleasure to talk to Hans Prenen about recent updates in CAR T cell therapy and the current findings from the alloSHRINK study (Clinical Trial Identifier: NCT03692429).
The abstract ‘Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC.’ (ABSTRACT NUMBER: 74) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.
Questions
- What are the limitations of current CAR T cell therapies? (0:25)
- Could you give us a brief overview of CYAD-101? (1:30)
- Could you tell us a little about the alloSHRINK study and its findings to date? (2:52)
Disclosures: Hans Prenen has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ASCO GI 2021 (Virtual).
